Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Chief Financial Officer | February 05, 2026 | February 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date February 05, 2026 · Filed February 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 137,973 |
Reported balance
After 2026-02-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 45,625 · Balance 137,973 F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. F2: Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 134,385 |
Reported balance
After 2026-02-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-09 · Sale · Disposed 3,588 · Balance 134,385 F3: On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2036-02-05 | Direct | 273,750 |
Reported balance
After 2026-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-05 · Grant · Acquired 273,750 · Balance 273,750 F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
F2: Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
F3: On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F4: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 12, 2026 02:03 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 3,588 | $13.45 | $48,258.60 |
DisclosureSEC source: 0001193125-26-047323 · ownership.xml · nonDerivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,385 F3 · kind: On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. Read SEC document |
| February 05, 2026 Filed Feb 12, 2026 02:03 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 273,750 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001193125-26-047323 · ownership.xml · derivative · entry 3 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 273,750 Underlying: Ordinary Shares · 273,750 shares Expires 2036-02-05 F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030. Read SEC document |
| February 05, 2026 Filed Feb 12, 2026 02:03 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 45,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-047323 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,973 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030. F2 · balance_after: Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · derivative · entry 16 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · derivative · entry 15 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,000 shares Expires 2030-03-03 F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $20.03 | $1,001,250.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 11 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F6 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F7 · balance_after: Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 50,000 | $10.48 | $524,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 10 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 36 | $20.25 | $729.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 9 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F6 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 36,000 | $8.17 | $294,120.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 8 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · derivative · entry 14 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,700 Underlying: Ordinary Shares · 50,000 shares Expires 2033-02-17 F5 · derivative.exercise_date: The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · derivative · entry 13 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 100,000 shares Expires 2032-01-01 F3 · derivative.exercise_date: The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · derivative · entry 12 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 60,000 shares Expires 2032-07-25 F2 · derivative.exercise_date: These share options are fully vested. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $18.00 | $900,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 7 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 50,000 | $4.75 | $237,500.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 6 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $13.20 | $660,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 5 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 50,000 | $15.00 | $750,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 4 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 100,000 | $3.14 | $314,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 3 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 60,000 | $13.20 | $792,000.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| December 08, 2025 Filed Dec 11, 2025 02:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 60,000 | $2.83 | $169,800.00 |
DisclosureSEC source: 0001193125-25-314736 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 252,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0000950170-25-015682 · ownership.xml · derivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,000 Underlying: Ordinary Shares · 252,000 shares Expires 2035-02-04 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2029. Read SEC document |
| February 04, 2025 Filed Feb 7, 2025 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015682 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,218 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2026 through February 8, 2029. F2 · balance_after: Includes 2,441 ordinary shares acquired on January 14, 2025, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| October 11, 2024 Filed Oct 12, 2024 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000950170-24-114422 · ownership.xml · derivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 25,000 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised via cash purchase in this reportable transaction were fully vested. Read SEC document |
| October 11, 2024 Filed Oct 12, 2024 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 25,000 | $2.48 | $62,000.00 |
DisclosureSEC source: 0000950170-24-114422 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 25, 2024 Filed Sep 28, 2024 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 17,146 | $9.00 | $154,314.00 |
DisclosureSEC source: 0000950170-24-110141 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F2 · balance_after: Includes 3,002 ordinary shares acquired on July 14, 2024, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| April 03, 2024 Filed Apr 6, 2024 00:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 15,630 | $6.17 | $96,421.47 |
DisclosureSEC source: 0000950170-24-042381 · ownership.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,921 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.115 to $6.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,431 ordinary shares acquired on January 14, 2024, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| February 05, 2024 Filed Feb 8, 2024 00:05 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 371,500 | $0.00 Strike: $3.87 | $0.00 |
DisclosureSEC source: 0000950170-24-012394 · ownership.xml · derivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,500 Underlying: Ordinary Shares · 371,500 shares Expires 2034-02-05 F1 · derivative.exercise_date: The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 01:15 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 37,062 | $4.75 | $176,118.62 |
DisclosureSEC source: 0000899243-23-018361 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,120 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 10, 2023. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.75 to $4.76 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,431 ordinary shares acquired on July 14, 2023, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| February 17, 2023 Filed Feb 18, 2023 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 272,700 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0000899243-23-005562 · doc4.xml · derivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,700 Underlying: Ordinary Shares · 272,700 shares Expires 2033-02-17 F4 · derivative.exercise_date: The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027. Read SEC document |
| February 16, 2023 Filed Feb 18, 2023 01:00 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 9,729 | $4.04 | $39,305.16 |
DisclosureSEC source: 0000899243-23-005562 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,751 F1 · kind: On February 16, 2023, the reporting person sold 9,729 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2023. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $4.03 to $4.18 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,500 ordinary shares acquired on July 14, 2022, and 3,413 ordinary shares acquired on January 14, 2023, under the issuer's 2019 Employee Share Purchase Plan. Read SEC document |
| July 25, 2022 Filed Jul 28, 2022 01:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-22-026928 · doc4.xml · derivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2032-07-25 F1 · derivative.exercise_date: The option vests as to 50% of the shares on July 25, 2023 and 50% on July 25, 2024. Read SEC document |
| May 05, 2022 Filed May 6, 2022 23:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 5,021 | $1.72 | $8,636.12 |
DisclosureSEC source: 0000899243-22-017133 · doc4.xml · nonDerivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,567 F2 · kind: On May 5, 2022, the reporting person sold 5,021 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.741 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2022 Filed May 6, 2022 23:10 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-017133 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,588 F1 · kind: On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:20 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 9,204 | $2.31 | $21,261.24 |
DisclosureSEC source: 0000899243-22-007066 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,588 F1 · kind: On February 16, 2022, the reporting person sold 9,204 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations. F2 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 1,500 ordinary shares acquired on July 14, 2021, and 1,500 ordinary shares acquired on January 14, 2022, under the issuer's 2019 Employee Share Purchase Plan (ESPP). Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:19 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $3.14 | $0.00 |
DisclosureSEC source: 0000899243-22-000670 · doc4.xml · derivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Ordinary Shares · 175,000 shares Expires 2032-01-01 F1 · derivative.exercise_date: The option vests as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026. Read SEC document |
| March 24, 2021 Filed Mar 24, 2021 23:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionShare Option (right to buy) · Derivative | 10,930 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-21-013331 · doc4.xml · derivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 10,930 shares Expires 2025-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share options that were exercised in this reportable transaction are fully vested. Read SEC document |
| March 24, 2021 Filed Mar 24, 2021 23:45 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | Exercise / conversionOrdinary Shares | 10,930 | $2.48 | $27,106.40 |
DisclosureSEC source: 0000899243-21-013331 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | SaleOrdinary Shares | 1,722 | $10.57 | $18,201.54 |
DisclosureSEC source: 0000899243-21-007201 · doc4.xml · nonDerivative · entry 2 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,862 F3 · kind: On February 16, 2021, the reporting person sold 1,722 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.50 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $10.48 | $0.00 |
DisclosureSEC source: 0000899243-21-007201 · doc4.xml · derivative · entry 3 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2031-02-01 F5 · derivative.exercise_date: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. Read SEC document |
| February 01, 2021 Filed Feb 19, 2021 00:09 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007201 · doc4.xml · nonDerivative · entry 1 Moran Kyle · CIK 0001657765 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,584 F1 · shares: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. F2 · balance_after: Includes 1,500 ordinary shares acquired under the issuer's 2019 Employee Share Purchase Plan (ESPP) on January 14, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.